More than an hour before the U.S. Court of Appeals for the Federal Circuit was set to hear a closely watched gene-patent case, hundreds of observers had already gathered outside the National Courts Building in downtown Washington to snag a seat.
The rows in Courtroom 201 filled up quickly, and the appeals court promptly dug into the dispute — whether a human gene is patent-eligible under Section 101 of the Patent Act.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
